2325 Stock Overview
Operates as a medical operation service provider in the People's Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 2325 from our risk checks.
Yunkang Group Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$7.00 |
| 52 Week High | HK$12.30 |
| 52 Week Low | HK$6.16 |
| Beta | -0.34 |
| 11 Month Change | -21.17% |
| 3 Month Change | -12.39% |
| 1 Year Change | -41.96% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -17.65% |
Recent News & Updates
Yunkang Group Limited's (HKG:2325) Shareholders Might Be Looking For Exit
Jul 05
Some Yunkang Group Limited (HKG:2325) Analysts Just Made A Major Cut To Next Year's Estimates
Apr 04Recent updates
Yunkang Group Limited's (HKG:2325) Shareholders Might Be Looking For Exit
Jul 05Some Yunkang Group Limited (HKG:2325) Analysts Just Made A Major Cut To Next Year's Estimates
Apr 04Estimating The Intrinsic Value Of Yunkang Group Limited (HKG:2325)
Sep 06Why We're Not Concerned About Yunkang Group Limited's (HKG:2325) Share Price
Jul 22We Think You Should Be Aware Of Some Concerning Factors In Yunkang Group's (HKG:2325) Earnings
Sep 29Yunkang Group Limited (HKG:2325) Shares Could Be 37% Below Their Intrinsic Value Estimate
Aug 19Shareholder Returns
| 2325 | HK Healthcare | HK Market | |
|---|---|---|---|
| 7D | -11.1% | -0.6% | 0.4% |
| 1Y | -42.0% | -23.3% | 12.0% |
Return vs Industry: 2325 underperformed the Hong Kong Healthcare industry which returned -23.3% over the past year.
Return vs Market: 2325 underperformed the Hong Kong Market which returned 12% over the past year.
Price Volatility
| 2325 volatility | |
|---|---|
| 2325 Average Weekly Movement | 7.4% |
| Healthcare Industry Average Movement | 8.2% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in HK Market | 18.9% |
| 10% least volatile stocks in HK Market | 4.3% |
Stable Share Price: 2325 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 2325's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 1,459 | Yong Zhang | www.yunkanghealth.com |
Yunkang Group Limited operates as a medical operation service provider in the People's Republic of China. The company offers diagnostic testing services for medical institution alliances, including setting up or upgrading diagnostic centers, the establishment of standard operating procedures for diagnostic testing, diagnostic consultation and staff training, procurement of equipment, smart internet of things, and logistics assistance. It also provides diagnostic outsourcing services comprising pathology tests; infectious disease diagnostic tests, including hepatitis B virus, tuberculosis, human papilloma virus, EB virus, rabies virus, and nucleic acid tests for respiratory pathogens; genetic reproduction, and screening tests.
Yunkang Group Limited Fundamentals Summary
| 2325 fundamental statistics | |
|---|---|
| Market cap | HK$4.19b |
| Earnings (TTM) | -HK$297.84m |
| Revenue (TTM) | HK$854.03m |
4.9x
P/S Ratio-14.1x
P/E RatioIs 2325 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2325 income statement (TTM) | |
|---|---|
| Revenue | CN¥794.58m |
| Cost of Revenue | CN¥522.26m |
| Gross Profit | CN¥272.32m |
| Other Expenses | CN¥549.42m |
| Earnings | -CN¥277.10m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.46 |
| Gross Margin | 34.27% |
| Net Profit Margin | -34.87% |
| Debt/Equity Ratio | 59.7% |
How did 2325 perform over the long term?
See historical performance and comparison